OVACE PLUS- sodium sulfacetamide liquid Mission Pharmacal Company

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

OVACE [®] PLUS WASH


Rx Only

FOR EXTERNAL USE ONLY. NOT FOR OPHTHALMIC USE.

DESCRIPTION:

Each gram contains 100 mg of sodium sulfacetamide in a vehicle consisting of: citric acid, disodium EDTA, fragrance, methylparaben, PEG-150 pentaerythrityl tetrastearate (and) aqua (and) PEG-6 caprylic/capric glycerides, PEG-60 almond glycerides, propylene glycol, propylparaben, purified water, sodium chloride, and sodium laureth sulfate (and) cocamide DEA (and) cocamidopropyl betaine (and) glycol stearate.

Sodium sulfacetamide is a sulfonamide with antibacterial activity. Sodium sulfacetamide is C $_8H_9N_2NaO_3S \cdot H_2O$ with molecular weight of 254.24. Chemically, sodium sulfacetamide is N-[(4-aminophenyl) sulfonyl]-acetamide, monosodium salt, monohydrate. The structural formula is:



Sodium sulfacetamide is an odorless, white, crystalline powder with a bitter taste. It is freely soluble in water, sparingly soluble in alcohol, while practically insoluble in benzene, in chloroform and in ether.

CLINICAL PHARMACOLOGY:

Sodium sulfacetamide exerts a bacteriostatic effect against sulfonamide sensitive Grampositive and Gram-negative microorganisms commonly isolated from secondary cutaneous pyogenic infections. It acts by restricting the synthesis of folic acid required by bacteria for growth, by its competition with para-aminobenzoic acid. There is no clinical data available on the degree and rate of systemic absorption of this product when applied to the skin or scalp. However, significant absorption of sodium sulfacetamide through the skin has been reported.

The following in vitro data is available but the clinical significance is unknown. Organisms that show susceptibility to sodium sulfacetamide are: Streptococci, Staphylococci, E. coli, Klebsiella pneumoniae, Pseudomonas pyocyanea, Salmonella species, Proteus vulgaris, Nocardia and Actinomyces.

INDICATIONS:

This product is intended for topical application in the following scaling dermatoses: seborrheic dermatitis and seborrhea sicca (dandruff). It also is indicated for the treatment of secondary bacterial infections of the skin due to organisms susceptible to sulfonamides.

CONTRAINDICATIONS:

This product is contraindicated in persons with known or suspected hypersensitivity to any of the ingredients of the product. This product is not to be used by patients with kidney disease.

WARNINGS:

Sulfonamides are known to cause Stevens-Johnson syndrome in hypersensitive individuals. Stevens-Johnson syndrome also has been reported following the use of sodium sulfacetamide topically. Cases of drug-induced systemic lupus erythematosus from topical sulfacetamide also have been reported. In one of these cases, there was a fatal outcome.

KEEP OUT OF THE REACH OF CHILDREN.

PRECAUTIONS:

FOR EXTERNAL USE ONLY. NOT FOR OPHTHALMIC USE.

General: Nonsusceptible organisms, including fungi, may proliferate with the use of this preparation.

Although rare, sensitivity to sodium sulfacetamide may occur. Therefore, caution and careful supervision should be observed when prescribing this drug for patients who may be prone to hypersensitivity to topical sulfonamides. If the use of this product produces signs of hypersensitivity or other untoward reactions, discontinue use of the preparation. Patients should be carefully observed for possible local irritation or sensitization during long-term therapy. Systemic toxic reactions such as agranulocytosis, acute hemolytic anemia, purpura hemorrhagica, drug fever, jaundice and contact dermatitis indicate hypersensitivity to sulfonamides. Particular caution should be employed if areas of denuded or abraded skin are involved. Systemic absorption of topical sulfonamides is greater following application to large, infected, abraded, denuded or severely burned areas. Under these circumstances, any of the adverse effects produced by the systemic administration of these agents could potentially occur, and appropriate observations and laboratory determinations should be performed.

Information for Patients: Patients should discontinue the use of this product if the condition becomes worse or if a rash develops in the area being treated or elsewhere. The use of this product also should be discontinued promptly and the physician notified if any arthritis, fever or sores in the mouth develop. Avoid contact with eyes, lips and mucous membranes.

Drug Interactions: This product is incompatible with silver preparations.

Carcinogenesis, Mutagenesis and Impairment of Fertility: Long-term animal studies for carcinogenic potential have not been performed on this product to date. Studies on reproduction and fertility also have not been performed. Chromosomal nondisjunction has been reported in the yeast, Saccharomyces cerevisiae, following application of sodium sulfacetamide. The significance of this finding to the topical use of sodium sulfacetamide in the human is unknown.

Pregnancy:*Category C.* Animal reproduction studies have not been conducted with this product. It is also not known whether this product can affect reproduction capacity or cause fetal harm when administered to a pregnant woman. This product should be used by a pregnant woman only if clearly needed or when potential benefits outweigh potential hazards to the fetus.

Nursing Mothers: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when this product is administered to a nursing woman.

Pediatric Use: Safety and effectiveness in children under the age of 12 years have not been established.

ADVERSE REACTIONS:

Reports of irritation and hypersensitivity to sodium sulfacetamide are uncommon. The following adverse reactions, reported after administration of sterile ophthalmic sodium sulfacetamide, are noteworthy: instances of Stevens-Johnson syndrome and instances of local hypersensitivity which progressed to a syndrome resembling systemic lupus erythematosus; in one case a fatal outcome was reported (see WARNINGS).

OVERDOSAGE:

The oral LD $_{50}$ of sulfacetamide in mice is 16.5 g/kg. In the event of overdosage, emergency treatment should be started immediately.

Manifestations: Overdosage may cause nausea and vomiting. Large oral overdosage may cause hematuria, crystalluria and renal shutdown due to the precipitation of sulfa crystals in the renal tubules and the urinary tract. For treatment, contact your local Poison Control Center or your doctor.

DOSAGE AND ADMINISTRATION:

Seborrheic dermatitis including seborrhea sicca - Shake well before using. Wash affected areas twice daily (morning and evening) or as directed by your physician. Avoid contact with eyes or mucous membranes. Wet skin and liberally apply to areas to be cleansed, massage gently into skin working into a full lather, rinse thoroughly, pat dry and repeat after 10 to 20 seconds. Rinsing with plain water will remove any excess medication. Repeat application as described above for 8 to 10 days or as directed by your physician. If skin dryness occurs it may be controlled by rinsing cleanser off sooner or using less frequently. Regular shampooing following the use of this product is not necessary, but the hair should be shampooed at least once a week. As the condition subsides, the

interval between applications may be lengthened. Applications once or twice weekly or every other week may prevent recurrence. Should the condition recur after stopping therapy, the application of this product should be reinitiated as at the beginning of treatment.

Secondary cutaneous bacterial infections - Shake well before using. Wash affected areas twice daily (morning and evening) or as directed by your physician. Avoid contact with eyes or mucous membranes. Wet skin and liberally apply to areas to be cleansed, massage gently into skin for 10 to 20 seconds working into a full lather, rinse thoroughly and pat dry. Rinsing with plain water will remove any excess medication. Repeat application as described above for 8 to 10 days or as directed by your physician. If skin dryness occurs it may be controlled by rinsing cleanser off sooner or using less frequently.

STORAGE:

Store at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C and 30°C (between 59°F and 86°F). Brief exposure to temperatures up to 40°C (104°F) may be tolerated provided the mean kinetic temperature does not exceed 25°C (77°F); however, such exposure should be minimized.

NOTICE: Protect from freezing and excessive heat. The product may tend to darken slightly on storage. Slight discoloration does not impair the efficacy or safety of the product. Keep bottle tightly closed.

Occasionally, a slight discoloration of fabric may occur when an excessive amount of the product is used and comes in contact with white fabrics. This discoloration, however, presents no problem, as it is readily removed by ordinary laundering without bleaches.

HOW SUPPLIED:

This product is supplied in the following size(s):

16 fl. oz. (473 mL) bottles, NDC 0178-0630-16


To report a serious adverse event or obtain product information, call 1-800-298-1087.

Manufactured by:

MISSION PHARMACAL COMPANY

San Antonio, TX 78230 1355

L663016R0222



PAGE 4

OVACE® PLUS WASH (sodium sulfacetamide 10%)

Rx Only

FOR EXTERNAL USE ONLY. NOT FOR OPHTHALMIC USE.

DESCRIPTION: Each gram contains 100 mg of sodium sulfacetamide in a vehicle consisting of: citric acid, disodium EDTA, fragrance, methylparaben, PEG-150 pentaerythirtly tetrastarate (and) acua (and) PEG-6 capylic/capric glycerides, PEG-60 almond glycerides, propyleng glycoi, propylparaben, purified water, sodium chloride, and sodium laureth sulfate (and) cocamide DEA (and) cocamidopropyl betaine (and) glycol stearate.

Sodium suifacetamide is a suifonamide with antibacterial activity. Sodium suifacetamide is CeHaNzNaO3S H₂O with molecular weight of 254.24. Chemically, sodium suifacetamide is N-{(4-aminopheny) suifonyI-acetamide, monosodium sait, monohydrata: Ine structural formula is:

Na⁺ H₂N - SO2NCOCH3 H20 Ì

Sodium sulfacetamide is an odoriess, white, crystalline powder with a bitter taste. It is freely soluble in water, sparingly soluble in aicohol, while practically insoluble in benzene, in chioroform and in ether.

soluble in alcohol, while practically insoluble in derezene, in crimororm and in surver. **CLINICAL PHARMACCLOGY:** Sodium sulfacetamide exerts a bacteriostatic effect against sulfonamide sensitive Gram-positive and Gram-negative microorganisms commonly isolated from secondary cutaneous progenic infections. It acts by restricting the synthesis of folic acid required by bacteria for growth, by its competition with para-aminobaroic acid. There is no clinical data available on the degree and rate of systemic absorption of this product when applied to the skin or scalp. However, significant absorption of sodium sulfacetamide through the skin has been reported.

The following in vitro data is available but the clinical significance is unknown. Organisms that show susceptibility to sodium suitacetamide en: Sterptococci, Staphylococci, E. coli, Klebsiella pneumoniae, Pseudomonas pyocyanea, Salmonella species, Proteus vulgaris, Nocardia and Actinomyces.

INDICATIONS: This product is intended for topical application in the following scaling dermatoses: seborrheic dermatitis and seborrhea sicca (dandruff). It also is indicated for the treatment of secondary bacterial infections of the skin due to organisms susceptible to sulfonamide

CONTRAINDICATIONS: This product is contraindicated in persons with known or suspected hypersensitivity to any of the ingredients of the product. This product is not to be used by patients with kidney disease.

WARNINGS: Sulfonamides are known to cause Stevens-Johnson syndrome in hypersensitive individuals. Stevens-Johnson syndrome also has been reported following the use of sodium sulfacetamide topically. Cases of drug-induced systemic lup crythematosus from topical sulfacetamide also have been reported. In one of these cases, there was a fatal outcome. KEP OUT OF REACH OF CHILDREN.

PRECAUTIONS: FOR EXTERNAL USE ONLY.

NOT FOR OPHTHALMIC US

PAGE 2

PAGE 1

aral: Nonsusceptible organisms, including fungi, may proliferate with the use of this preparation.

General: Nonsusceptible organisms, including rung, may provinerate wirm the use of this preparation. Although rans, pensitivity to sodium suffacetamide may occur. Therefore, caution and careful supervision should be obsarved when prescribing this drug for patients who may be prone to hypersensitivity to logical sufformanide. If the use of this product produces signs of hypersensitivity or other untoward reactions, discontinue use of the preparation. Patients should be carefully observed for possible local initiation or sensitization during long-term therapy. Systemic toxic reactions such as agranulocytosis, acute hemolytic anemia, purpura hemorrhagica, drug fever, jaundice and contact dermatifis indicate hypersensitivity to sufformalides. Particular caution should be employed if rares of denuded or abraded skin are involved. Systemic absorption of topical sufformatides is greater following application to large, infected, abraded, elevated or severely burned areas. Under these circumstances, any of the adverse effects produced by the systemic administration of these agents could potentially occur, and appropriate observations and laboratory determinations should be performed.

Information for Patients: Patients should discontinue the use of this product if the condition becomes worse or if a rash develops in the area being treated or elsewhere. The use of this product also should be discontinued promptly and the physician notified if any arthritis, fever or sores in the mouth develop. Avoid contact with eyes, lips and mucous membranes.

Drug Interactions: This product is incompatible with silver preparations.

Carcinogenesis, Mutagenesis and Impairment of Fertility: Long-term animal studies for carcinogenic potential have not been performed on this product to date. Studies on reproduction and fertility also have not been performed. Chromosomal nondisjunction has been reported in the yeast, Saccharomyces cerevisiae, following application of sodium suffacetamide. The significance of this finding to the topical use of sodium suffacetamide in the luman is unknown.

Pregnancy: Category C. Animal reproduction studies have not been conducted with this product. It is also not known whether this product can affect reproduction capacity or cause fetal harm when administered to a pregnant woman. This product should be used by a pregnant woman only if clearly needed or when potential benefits outweigh potential hazards to the fetus.

Nursing Mothers: It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when this product is administered to a nursing work


Pediatric Use: Safety and effectiveness in children under the age of 12 years have not been established

ADVERSE REACTIONS: Reports of irritation and hypersensitivity to sodium sulfacetamide are uncommon. The following adverse reactions, reported after administration of sterile ophthalmic sodium sulfacetamide, are noteworthy: instances or Stevens-Johnson syndrome and instances of local hypersensitivity which progressed to a syndrome resembling systemic lupus erythematosus; in one case a fatal outcome was reported (see WARNINGS).

OVERDOSAGE: The oral LD50 of sulfacetamide in mice is 16.5 g/kg. In the event of overdosage, emergency treatment should be started immediately

Manifestatione: Overdosage may cause nausea and vomiting. Large oral overdosage may cause hematuria, crystalluria and renal shutdown the la the precipitation of sulfa crystals in the renal tubules and the urinary tract. For treatment, contact your local Poison Control Center or your doctor.

PAGE 3



		Inare	dient Nam	e		Basis of Stre	nath	Strengt
SULFACETAMID JNII:4965G3J0F5)		-		(SULFACETAMIDE ·		SULFACETAMIDE SODIUM	_	100 mg in 1 mL
Inactive Ing	redie	nts						
			Ingredi	ent Name				Strength
EDETATE DISOI	DIUM (JNII: 7FLD9	1C86K)					
METHYLPARABI	EN (UN	I: A2I8C7HI	9T)					
PEG-6 CAPRYLI	C/CAPI	RIC GLYCE	RIDES (UNII: (GO50W2HWO8)				
COCO DIETHAN	OLAM	I DE (UNII: 9	2005F972D)					
CITRIC ACID MO	олону	DRATE (UN	III: 2968PHW8	QP)				
PEG-150 PENTA	ERYTH		RASTEARAT	E (UNII: 8L4OOQ7	6AM)			
PEG-60 ALMON	D GLY	CERIDES (l	JNII: 4Y0E6511	NOF)				
PROPYLENE GL	YCOL	UNII: 6DC9	Q167V3)					
PROPYLPARABE	N (UNI	I: Z8IX2SC1	.OH)					
WATER (UNII: 05	9QF0K	00R)						
SODIUM CHLOP	RIDE (U	NII: 451W47	'IQ8X)					
SODIUM LAURE	IH-3 S	ULFATE (U	INII: BPV390U	4P0)				
SODIUM LAURE COCAMIDOPRO GLYCOL STEAR	PYL BI	ETAINE (UN	III: 50CF3011					
COCAMIDOPRO GLYCOL STEAR Product Cha	PYL BI ATE (U	ETAINE (UN NII: 0324G6 Eristics	III: 50CF3011 6D0E)	KX)				
COCAMIDOPRO GLYCOL STEAR	PYL BI ATE (U	ETAINE (UN NII: 0324G6 Eristics	III: 50CF3011	KX)		Score		
COCAMIDOPRO GLYCOL STEAR Product Cha	PYL BI ATE (U	ETAINE (UN NII: 0324G6 Eristics	III: 50CF3011 6D0E)	KX)		Score Size		
COCAMIDOPRO GLYCOL STEAR Product Cha Color	PYL BI ATE (U	ETAINE (UN NII: 0324G6 Eristics	III: 50CF3011 6D0E)	KX)				
COCAMIDOPRO GLYCOL STEAR Product Cha Color Shape	PYL BI ATE (U	ETAINE (UN NII: 0324G6 Eristics	III: 50CF3011 6D0E)	KX)		Size		
COCAMIDOPRO GLYCOL STEAR Product Cha Color Shape Flavor	PYL BI ATE (U	ETAINE (UN NII: 0324G6 Eristics	III: 50CF3011 6D0E)	KX)		Size		
COCAMIDOPRO GLYCOL STEAR Product Cha Color Shape Flavor	PYL BI ATE (U	ETAINE (UN NII: 0324G6 Eristics	III: 50CF3011 6D0E)	KX)		Size		
COCAMIDOPRO GLYCOL STEAR Product Cha Color Shape Flavor Contains	PYL BI ATE (U	ETAINE (UN NII: 0324G6 Eristics yellow (Off	III: 50CF3011 6D0E)	KX) w)	M	Size	Mar	keting En Date
COCAMIDOPRO GLYCOL STEAR Product Cha Color Shape Flavor Contains Packaging # Item Code	PYL BI ATE (U hract	eristics yellow (Off	III: 50CF3O11 6D0E) white to yello ackage De	KX) w)		Size Imprint Code	Mar	
COCAMIDOPRO GLYCOL STEAR Product Cha Color Shape Flavor Contains Packaging # Item Code NDC:0178-	PYL BI ATE (U hract	eristics yellow (Off Pranner of the second s	III: 50CF3O11 6D0E) white to yello ackage De	KX) w) scription		Size Imprint Code arketing Start Date	Mar	
COCAMIDOPRO GLYCOL STEAR Product Cha Color Shape Flavor Contains Packaging # Item Code NDC:0178-	PYL BI ATE (U Aracte Aracte Com	eristics yellow (Off mL in 1 BO bination Pro	III: 50CF3011 6D0E) white to yello white to yello ackage Des TLE, PLASTIC	KX) w) scription		Size Imprint Code arketing Start Date	Mar	
COCAMIDOPRO GLYCOL STEAR Product Cha Color Shape Flavor Contains Packaging # Item Code 1 NDC:0178- 0630-16	PYL BI ATE (U Aract Aract Aract Com	eristics yellow (Off Pa mL in 1 BO bination Pro	III: 50CF3011 6D0E) white to yello ackage Des TTLE, PLASTIC oduct	KX) w) scription ; Type 0: Not a	09/	Size Imprint Code arketing Start Date		

Labeler - Mission Pharmacal Company (008117095)